A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Sutimlimab (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Cadenza
- Sponsors Bioverativ
- 04 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Aug 2020.
- 04 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Aug 2020.
- 06 Mar 2018 According to a Bioverativ media release, first patient has been dosed in this trial.